P128 Phase II trial with letrozole (2.8 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

✍ Scribed by A. Lombart-Cussac; A. Galán; C. Fuster Diana; E. Buch; V. Carañana; A. Rodriguez-Lescure; C. Vázquez; A. Guerrero; A. Ruiz; V. Guilem Porta

• Book ID: 114316041
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 60 KB
• Volume: 16
• Category: Article
• ISSN: 0960-9776
• DOI: 10.1016/s0960-9776(07)70188-1